Ignite Creation Date:
2024-05-06 @ 4:12 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04900818
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2021-05-20
Brief Title:
Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
Sponsor:
I-Mab Biopharma US Limited
Organization:
I-Mab Biopharma US Limited
Study Overview
Official Title:
A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label multi-center multiple dose Phase 1 study to evaluate the safety tolerability MTD PK and PD of TJ033721 in subjects with advanced or metastatic solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None